26/04/2010 - Press release
The medical data of more than 27 million Europeans will be analysed and more than 250 pharmacological compounds will be studied
Cardiac arrhythmia caused by medications is a priority in pharmacological safety as they are difficult to predict. Sudden cardiac death and Torsades de Pointes (TDP) are serious side effects of some antipsychotic, antihistamine and anti-infective drugs that induce prolonged QT intervals. The QT interval is a measure of the time between the Q and T cardiac waves that are recorded in electrocardiograms. If it is abnormally prolonged, arrhythmias may be caused. The normal value is between 0.30 and 0.44 seconds in men and 0.45 seconds in women.
Although its incidence is not very frequent and not all medications that prolong the QT interval cause these side effects, the difficulty of determining which of them can cause serious arrhythmic side effects in recent years has led to the removal of some of these medications from the market or restrictions on their use.
ARITMO arose out of the need to identify not only which medications prolong the QT interval, but also those that can cause serious side effects as well as discover the factors that are associated with this risk. The project, which will last a total of 36 months, will analyse the arrhythmogenic potential of more than 250 antipsychotic, antihistamine and anti-infective drug compounds on the initiative of the European Medicines Agency Pharmaco-Surveillance Group.
The ARITMO project (the complete title is “Arrhythmogenic Potential of Medicines”) has received a 2.7 million euro subsidy from the European Commission (7th Framework Programme). It will be carried out by a consortium of 17 internationally renowned research institutions, led by Dr. Miriam Sturkenboom from the Erasmus Medical Centre of Rotterdam (Holland) who will create a common protocol for the participating databases and will conduct surveillance studies. Combining the databases and surveillance systems will make it possible to study one of the largest data collections available and be equipped with great potential to examine the risks deriving from the differences in prescription patterns between southern and northern Europe.
The IMIM Foundation, through its European Project Coordination Office, will be responsible for coordinating this management and the IMIM (Hospital del Mar Research Institute) Chemical Genomics Laboratory, led by Jordi Mestres, will be responsible for preparing the cardiac safety profiles for the medications.
A multi-disciplinary approach will be used to achieve the ARITMO objectives such as:
Integrating all of the knowledge from all of these actions will help evaluate the risks and benefits of the medications in order to make treatment decisions. The database gathering all the knowledge generated will include a score assigned based on the weight of the quality and soundness of the information as well as a risk classification aimed at doctors so as to enable improved informed treatments and decision making when prescribing drugs.
Participating institutions: Erasmus University Medical Center, Netherlands; Fundació IMIM, Spain; London School for Hygiene and Tropical Medicine, United Kingdom; Alma Mater Studiorum-Università di Bologna, Italy ; Universitaet Bremen, Germany ; University of Newcastle, United Kingdom ; Université Victor-Segalen Bordeaux 2, France; Fondazione Salvatore Maugeri Clinica del Lavoro e Della Riabilitazione – IRCCS, Pavia, Italy ; Charite – Universitaetsmedizin Berlin, Germany; Università Degli Studi di Verona, Italy; St. Gerorge’s Hospital Medical School, United Kingdom; AstraZeneca, Sweden; PHARMO Institute, Netherlands; Fondazione Scientifica SIMG-ONLUS, Italy; Aarhus Universitetshospital, Aarhus Sygehus, Denmark; Academisch Medisch Centrum bij de Universiteit van Amsterdam, Netherlands; Drug Safety Research Trust, United Kingdom.
Project website: www.aritmo-project.org